La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Royalty Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Royalty Pharma..

Royalty Pharma (NASDAQ:RPRX) Azioni, Catena delle Opzioni

Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Long Ideas

News

Markets

Media

Trading Ideas

RPRX

Jim Cramer esprime la sua fiducia in Walmart, definendola una delle migliori scelte finanziarie attuali nel mercato.

Jim Cramer consiglia di comprare Walmart: &#34;È un&#39;azione molto buona&#34;

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma PLC

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.9% to $0.7 during Friday's after-market session. The company's market cap stands at $1.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 24.8% to $0.24. The company's market cap stands at $7.7 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares rose 7.75% to $1.25. The company's market cap stands at $18.2 million. </li>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) stock increased by 6.59% to $16.33. The market value of their outstanding shares is at $419.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares moved upwards by 6.45% to $10.98. The market value of their outstanding shares is at $134.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 6.17% to $2.58. The market value of their outstanding shares is at $2.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares decreased by 23.6% to $5.03 during Friday's after-market session. The market value of their outstanding shares is at $270.7 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares decreased by 10.38% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares declined by 7.86% to $0.36. The market value of their outstanding shares is at $9.1 million. </li>
<li>SINTX Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 6.82% to $2.6. The market value of their outstanding shares is at $6.5 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 5.53% to $1.71. The market value of their outstanding shares is at $2.5 million. </li>
<li>Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) shares fell 5.03% to $30.82. The company's market cap stands at $12.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJDX

IMNN

KLTO

MHUA

PRTA

REVB

SINT

TRML

VTAK

WORX

12 Health Care Stocks Moving In Friday's After-Market Session

<ul>
<li>Received overwhelming shareholder approval with 99.9% of votes cast in favor</li>
<li>Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments</li>
<li>Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years</li>
<li>Royalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation</li>
</ul>
&nbsp;Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the "Meeting"), marking a key milestone for the company.
"We are pleased to announce shareholder approval of our manager internalization, an important step that strengthens our corporate governance, enhances transparency, and further aligns our leadership team with shareholder interests," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "We are grateful for the strong support from our shareholders, and remain focused on delivering long-term value through our differentiated, innovation-focused business model."
With shareholder approval, Royalty Pharma will proceed with its transition from an external manager model to an integrated corporate structure, with the Royalty Pharma executive team and employees becoming direct employees of the company.
Key Benefits to Shareholders
The transaction is expected to result in multiple benefits for shareholders. On a financial basis, the acquisition is expected to reduce costs and enhance economic returns on investments. Specifically, the acquisition will generate cash savings of greater than $100 million in 2026 and greater than $175 million in 2030, and drive cumulative savings of greater than $1.6 billion over ten years. The acquisition also increases shareholder alignment, enhances corporate governance, ensures management continuity, maximizes employee retention as a result of the 5 to 9 year vesting of the shares received by management and simplifies Royalty Pharma's corporate structure. Lastly, internalizing the Manager has the potential to expand Royalty Pharma's&nbsp;shareholder base&nbsp;and further enhance the company's valuation over time.

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition With 99.9% Votes Cast In Favor

Raised financial guidance for full year 2025 (excludes contribution from future transactions)
<ul>
<li>Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, representing expected growth of 6% to 12%.</li>
<li>The company expects to update 2025 guidance for payments and operating and professional costs and interest paid after the closing of the internalization transaction, which is expected in the second quarter of 2025.</li>
</ul>

Guidance

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.975B-$3.125B (Prior $2.9B-$3.05B)

Earnings

Earnings Misses

Royalty Pharma Q1 Adj. EPS $1.06 Misses $1.59 Estimate,

Royalty Pharma Q1 Sales $568.00M Miss $705.34M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

<ul>
<li>Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland</li>
<li>Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand for ADSTILADRIN</li>
<li>Milestone prompts final $200 million payment from Royalty Pharma</li>
</ul>
Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN&#xAE; (nadofaragene firadenovec-vncg). The approval expands Ferring's manufacturing capabilities to three cutting-edge sites dedicated to bringing ADSTILADRIN to patients and secures a final $200 million payment from Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) as part of a royalty-based financing agreement <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fferringusa.com%2F%3Fpress%3Droyalty-pharma-and-ferring-pharmaceuticals-enter-into-us-500-million-royalty-agreement-for-new-intravesical-gene-therapy-adstiladrin-nadofaragene-firadenovec-vncg&amp;esheet=54242093&amp;newsitemid=20250424910916&amp;lan=en-US&amp;anchor=announced+in+2023&amp;index=1&amp;md5=a6e5cb251b736a868f536b3d9f50ebbf">announced in 2023</a>.
ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the FDA for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). Bladder cancer is the sixth most diagnosed cancer in the United States, and the majority of patients are diagnosed with non-muscle invasive disease.

FDA Approves Second Drug Product Manufacturing Facility For ADSTILADRIN; Ferring Secures Final $200M Payment From Royalty Pharma

Royalty Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NYSE">RPRX</a>) short percent of float has fallen 10.08% since its last report. The company recently reported that it has 13.75 million shares sold short, which is 3.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Royalty Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742404527_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Royalty Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Royalty Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Royalty Pharma's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Royalty Pharma?

Royalty Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NYSE">RPRX</a>) short percent of float has fallen 3.08% since its last report. The company recently reported that it has 16.13 million shares sold short, which is 3.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Royalty Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740409230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Royalty Pharma has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Royalty Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Royalty Pharma's peer group average for short interest as a percentage of float is 3.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Royalty Pharma's Recent Short Interest

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company&nbsp;<a target="_blank" href="https://investors.biogen.com/static-files/a4eadd7a-6e77-4110-8289-94816df02324" rel="noreferrer noopener">reported</a> sales of&nbsp;$2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.
Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43635908/what-to-expect-from-alzheimers-drugmaker-biogens-q4-earnings-on-wednesday" rel="noreferrer noopener">from $464.7 million</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42973945/fda-to-review-under-the-skin-weekly-autoinjector-for-biogen-eisais-alzheimers-drug-leqembi" rel="noreferrer noopener">FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi</a>
Rare disease revenue&nbsp;increased&nbsp;13% year over year (up 15% on constant currency) to $535.3 million. Spinraza's revenue increased to $421.4 million from $412.6 million a year ago.
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.2 million during the quarter.
In Alzheimer's disease, Biogen said Leqembi fourth quarter global in-market sales of approximately $87 million, including U.S. in-market sales of approximately $50 million, representing good continued sequential growth.
Postpartum depression drug Zurzuvae's fourth-quarter sales reached $22.9 million.
Guidance: Biogen forecasts a full year 2025 adjusted EPS of $15.25-$16.25&nbsp;versus a consensus of $16.34.
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
For 2025, as compared to 2024, Biogen expects the operating margin percentage to remain relatively flat.
The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025.
Since the program was initiated in 2023, approximately $400 million of net savings have been achieved, and Biogen expects to realize the balance by the end of 2025.
Biogen expects combined Non-GAAP R&amp;D and SG&amp;A expenses to total approximately $3.9 billion in 2025.
Royalty Pharma plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) agreed to provide Biogen with R&amp;D funding of up to $250 million for litifilimab for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab is currently in Phase 3 trials for SLE and CLE, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43651925/royalty-pharma-announces-r-d-funding-collaboration-with-biogen" rel="noreferrer noopener">with results expected between 2026 and 2027</a>.
Price Action: BIIB stock is down 6.74% at $130&nbsp;at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43653157/johnson-johnson-explores-sale-of-stroke-device-maker-cerenovus-as-medtech-overhaul-accelerates" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates</a></li>
</ul>

Biotech

Large Cap

Health Care

Financing

Contracts

General

BIIB

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

Royalty Pharma Entered Into An Agreement With Biogen To Provide Research And Development Funding Of Up To $250M For Litifilimab, A First-in-class Investigational Drug Candidate In Phase 3 With Demonstrated Proof-of-concept In Both Systemic Lupus Erythematosus And Cutaneous Lupus Erythematosus

U.S. stocks edged marginally lower on Tuesday after Federal Reserve Chair Jerome Powell reiterated that the central bank is in no hurry to cut interest rates during his testimony before the Senate Banking Committee, offering little <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43628752/feds-powell-reiterates-no-hurry-to-cut-interest-rates-as-inflation-remains-somewhat-elevated">support for risk assets.</a>
Investors remained on edge ahead of Wednesday's key inflation report, with the Bureau of Labor Statistics set to release the January Consumer Price Index.
The S&amp;P 500 dipped 0.1%, the Nasdaq 100 declined 0.2%, and small-cap stocks underperformed. Bucking the trend, the Dow Jones Industrial Average posted a marginal 0.1% gain.
Company-wise, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged 7%, after Vice President J.D. Vance indicated that artificial intelligence chips will be manufactured in the U.S.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell by over 4%, reaching the lowest levels in eleven weeks, pressured by weak January auto sales in China.
Geopolitical tensions flared as the European Union threatened countermeasures in response to President Donald Trump's announcement of 25% tariffs on aluminum and steel.
Long-dated Treasury yields moved higher, with the 10-year yield rising to 4.54%. Yet, the broader dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – weakened, down 0.2%. 
Gold paused for a breather, remaining flat at $2,900 per ounce. Oil prices inched up by 1%, eyeing the third straight session of gains. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) weakened 1.3% to $96,000. 
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,526.92</td>
<td>0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,064.30</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,714.53</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,273.29</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.1% down to $604.07.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.1% up to $445.06.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.3% to $527.55.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.7% to $225.34.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.4%; the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) rose 2.4% after KeyBanc raised the stock to Overweight.</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) surged 5% after Elliott Investment Management urged the company to sell or spin off its midstream business, estimating its value at over $40 billion.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained 2.8%, and Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 2% amid speculation about a potential AI partnership for iPhone users in China.</li>
</ul>
Stocks reacting to earnings reports include: 
<ul>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 3.8%</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 7.5%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 3.7%</li>
<li>DuPont de Nemours Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>): up 7.8%</li>
<li>Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>): down 5.6%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>): down 6.5%</li>
<li>Masco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): up 0.6%</li>
<li>WK Kellogg Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>): down 0.7%</li>
<li>Arvinas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>): down 6.3%</li>
<li>AutoNation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>): down 3.3%</li>
<li>Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>): down 4.7%</li>
<li>Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 1.8%</li>
<li>Fidelity National Information Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>): down 14.9%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>): up 6.2%</li>
<li>IPG Photonics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>): down 5.9%</li>
<li>LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>): up 3.5%</li>
<li>Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>): down 5.4%</li>
<li>MYT Netherlands Parent BV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>): up 19.4%</li>
<li>NNN REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>): up 5.8%</li>
<li>Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>): up 1.4%</li>
<li>Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>): down 1.8%</li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>): down 3.5%</li>
<li>USA Compression Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>): down 2.9%</li>
<li>Wesco International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>): up 2.1%</li>
</ul>
Companies reporting after the close include:
<ul>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>)</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</li>
<li>Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</li>
<li>Primerica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>)</li>
<li>Allison Transmission Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>)</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</li>
<li>Brighthouse Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>)</li>
<li>DoorDash Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NYSE">DASH</a>)</li>
<li>W. P. Carey Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>)</li>
<li>Agree Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>)</li>
<li>Red Rock Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>)</li>
<li>Teradata Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>)</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43632327/steel-stocks-breakout-analyst-sees-bullish-setup-for-us-steel-nucor-steel-dynamics">Tariffs Drive Steel Stock Gains As Analyst Highlights Catalysts For Nucor, US Steel</a></li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAPL

ALSN

ARVN

BABA

Brighthouse Financial, Inc. - Common Stock

CARR

DASH

SPDR Dow Jones Industrial Average ETF Trust

GILD

INTC

IPGP

LCII

LDOS

MYTE

SPGI

STLD

TSLA

USAC

PowerShares DB US Dollar Index Bullish Fund

WELL

Select Sector SPDR-Consumer Discretionary

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 million by 12.50 percent. This is a 0.34 percent decrease over sales of $596.00 million the same period last year.

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

ANGI

ATEX

ATOM

BIOX

CFLT

CRNT

CURB

ELMD

EXEL

FORR

FRSH

GLAD

GNSS

HIVE

JRSH

LYFT

MCRI

OESX

SAGE

SHOP

SMCI

SMWB

SQNS

TYGO

UFCS

UPST

YTRA

Earnings Scheduled For February 11, 2025

<ul>
<li>Total proceeds of $530 million on $300 million original 2022 investment</li>
<li>Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions</li>
</ul>
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive return by monetizing these future fixed payments at a low discount rate of 5.35% and will redeploy these proceeds into higher returning investment opportunities, including repurchasing its shares and acquiring attractive new royalties.

Royalty Pharma Secures $530M From MorphoSys Bonds, Exceeding $300M 2022 Investment; Plans Share Repurchases, Royalty Acquisitions

Comments

Royalty Pharma

Royalty Pharma (RPRX) Opzioni

Royalty Pharma (NASDAQ:RPRX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO